Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MONONANOCHEM

Financiado

Cerrado

In vivo engineering of monocytes loaded with nano chemotherapeutic formulations...

In vivo engineering of monocytes loaded with nano chemotherapeutic formulations a novel live cell mediated drug delivery system for the treatment of cancer The success of current antitumoural therapies largely depends on the availability of appropriate drug delivery strategies, which have to allow the penetration of these drugs through the tumoural microenvironment. The knowledge rel... ver más

31/12/2018

HUMANITAS MIRASOLE...

168K€

Presupuesto del proyecto: 168K€

Líder del proyecto

HUMANITAS MIRASOLE SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

MSCA-IF-2015-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

HUMANITAS MIRASOLE SPA

168.28K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2017-017 NANO-IMMUNOTHERAPY: INTRACELLULAR TARGETING OF CANCER CELLS... 100K€ Cerrado

NeoNaNo Neoadjuvant Nanomedicines for vascular Normalization 1M€ Cerrado

NANOTAM Development and Evaluation of Nanomedicines for Cancer Treat... 168K€ Cerrado

PCIN-2017-129 NANO-INMUNOTERAPIA: TARGETING INTRACELULAR DE CELULAS TUMORA... 150K€ Cerrado

FJC2020-044220-I Re-educating tumor associated macrophages with nanoparticle... 53K€ Cerrado

PID2019-105416RB-I00 GRANULOS DE SECRECION ARTIFICIALES PARA LA ENTREGA REMOTA DE... 145K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2016-04-01
Fecha Fin: 2018-12-31

Líder del proyecto

HUMANITAS MIRASOLE SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 168K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The success of current antitumoural therapies largely depends on the availability of appropriate drug delivery strategies, which have to allow the penetration of these drugs through the tumoural microenvironment. The knowledge related to the cellular heterogeneity of the tumours has advanced enormously in the last years. Tumour associated macrophages (TAM) can represent up to 50% of the tumour mass. TAM are derived from circulating monocytes, which are recruited from the peripheral blood towards the tumour in response to a broad range of molecular signals (i.e. cytokines). Recently several studies are focused on the development of therapeutic strategies targeting TAM, however, the possibility to use monocytes, with excellent ability to infiltrate the abnormal tumoural tissue, to deliver chemotherapeutic drugs into the tumour has been hardly explored. Here, we aim to use the host monocyte/macrophage cells, with high ability to infiltrate the tumoural tissues, to deliver nano-chemotherapeutic formulations into the bulk of the tumour. We will develop Nano-Formulations consisting in Hyaluronic Acid (HA) nanostructures decorated with beta-glucans, allowing the targeting of specific receptors on the host circulating monocytes (Dectin-1), and at the same time, the loading of chemotherapeutic drugs into these cells. Cytotoxic drugs inducing immunogenic cell death (i.e. bortezomib), and thus the recruitment of new monocytes, will be used to enhance the efficacy of the therapy. Overall, we will use Monocytes loaded with Nano-ChemoTherapeutic Formulations (MNCTFs) as a new strategy to deliver cytotoxic drugs towards the tumoural cells, taking advantage of the infiltration ability of the monocytes/macrophages into tumour microenvironment. The MNCTFs will be tested using appropriate in vitro 2D and 3D tumour models and in vivo murine tumour models. We expect that this new live-cell mediated drug delivery system will provide greater progress in the treatment of cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores